REG - LungLife AI, INC - Confirmation of AGM

LungLife AIAnnouncement

03/06/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC8939Qa&default-theme=true

RNS Number : 8939Q  LungLife AI, INC  03 June 2024

LungLife AI, Inc.

("LungLife" or the "Company")

 

Confirmation of AGM

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, confirms that its Annual General Meeting ("AGM") will be held at 4:00
P.M. (BST) on Wednesday 5 June 2024, at Investec Bank plc, 30 Gresham Street,
London, EC2V 7QP.

 

For those shareholders who would like to dial into the meeting, please
register by emailing LungLifeAI@walbrookpr.com or calling +44 (0)20 7933 8780
and the dial in link will be sent by email.

 

The results of voting on the resolutions will be announced via a regulatory
information service and posted on the Company's website as soon as practicable
after the AGM.

 

For further information please contact:

 

 LungLife AI, Inc.                                     www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                      Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)        Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                               Tel: +44 (0) 20 3841 6202
 Tom Nicholson / Cameron Duncan

 Walbrook PR Limited                                    Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                       (mailto:LungLifeAI@walbrookpr.com)
 Alice Woodings / Phillip Marriage                     Mob: 07407 804 654 / 07867 984 082

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
Our Vision is to invert the 20:80 ratio such that in years to come at least
80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABBGDLSSGDGSX